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Abstract
Background: This trial was conducted to evaluate the safety and immunogenicity of two virosome formulated malaria
peptidomimetics derived from Plasmodium falciparum AMA-1 and CSP in malaria semi-immune adults and children.
Methods: The design was a prospective randomized, double-blind, controlled, age-deescalating study with two
immunizations. 10 adults and 40 children (aged 5–9 years) living in a malaria endemic area were immunized with PEV3B
or virosomal influenza vaccine InflexalHV on day 0 and 90.
Results: No serious or severe adverse events (AEs) related to the vaccines were observed. The only local solicited AE
reported was pain at injection site, which affected more children in the InflexalHV group compared to the PEV3B group
(p = 0.014). In the PEV3B group, IgG ELISA endpoint titers specific for the AMA-1 and CSP peptide antigens were significantly
higher for most time points compared to the InflexalHV control group. Across all time points after first immunization the
average ratio of endpoint titers to baseline values in PEV3B subjects ranged from 4 to 15 in adults and from 4 to 66 in
children. As an exploratory outcome, we found that the incidence rate of clinical malaria episodes in children vaccinees was
half the rate of the control children between study days 30 and 365 (0.0035 episodes per day at risk for PEV3B vs. 0.0069 for
InflexalHV; RR = 0.50 [95%-CI: 0.29–0.88], p = 0.02).
Conclusion: These findings provide a strong basis for the further development of multivalent virosomal malaria peptide
vaccines.
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Introduction
The development of an effective malaria vaccine is regarded as
one cornerstone in the fight against this deadly disease and to
achieve its eventual elimination [1]. Malaria vaccine development
is hindered by the fact that the parasite proceeds through a
succession of stages in the human host, with stage specific
expression of proteins, a high level of antigen polymorphism,
redundancy of essential invasion pathways in host cells, and
utilization of a number of immune evasion mechanisms [2]. The
lack of an in vitro correlate of protection in malaria and detailed
knowledge of the natural host parasite interaction contributes
significantly to the slow progress in this field [3]. It is currently
assumed that an effective malaria vaccine will likely be comprised
of antigens of several developmental stages of the parasite [4].
The circumsporozoite protein (CSP), the major surface protein
of the P. falciparum sporozoite, has been the focus of numerous
efforts to develop a pre-erythrocyte vaccine that aims at prevention
of hepatocyte invasion by sporozoites [5]. The CSP forms a dense
coat covering the entire surface of the sporozoites, and is critical
for sporozoite localization and development of the parasites’ liver
stage [6]. Antibodies against CSP are primarily directed against
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the central repeat region [7]. We have developed a synthetic
peptide closely resembling the natural conformation of the CSP
repeat region [8]. The peptide-phospatidylethanolamine (PE)
conjugate is named UK-39 and represents a circularized structure
of five NANP repeats [9]. Immunization of rodents with UK-39
coupled to the surface of immuno-potentiating influenza virosomes
(IRIV) resulted in high titers of sporozoite cross-reactive
antibodies. UK-39 specific IgG inhibited migration and invasion
of human hepatocytes by sporozoites providing evidence for
protective capacity [10]. The apical membrane antigen 1 (AMA-
1), is essential for erythrocyte invasion of P. falciparum [11,12,13]. It
is localized within the apical complex and translocated to the
merozoite surface before invasion of erythrocytes commences. It is
also expressed in sporozoites [14]. AMA-1-specific antibodies can
specifically block the entry of merozoites and sporozoites into
erythrocytes and hepatocytes, respectively [14,15,16]. A cyclized
synthetic peptide of 49 amino acids (named AMA49-C1 as PE
conjugate), comprising residues 446–490 of the semi-conserved
loop I of domain III has been shown to induce asexual blood stage
parasite growth inhibitory antibodies [17].
IRIVs are reconstituted viral coats of influenza viruses lacking
the infectious nucleo-capsid RNA but retaining their target cell
surface binding and fusogenic activity [18]. They are prepared by
detergent removal from a mixture of natural and synthetic
phospholipids and influenza surface glycoproteins. The haemag-
glutinin of the influenza virus is a fusion-inducing membrane
glycoprotein, which facilitates antigen delivery to immunocompe-
tent cells. Based on pre-clinical studies, it is generally assumed that
during vaccine inoculation, influenza antigen-specific CD4 T-cells
provide essential T-cell help for B-cells recognizing synthetic non-
influenza peptides coupled to the surface of virosomes [19].
Encapsulated in the virosome lumen antigens may also be used to
elicit CD8 T-cell responses. In contrast to live viral vectors like
adenovirus, which need the infection of target cells for the
induction of immune responses against heterologous antigens, the
pre-existing influenza specific immune response did not negatively
interfere with the induction of malaria peptide-specific humoral
and cellular immune responses [20]. Studies in rodents demon-
strated that pre-existing anti-influenza immunity enhances the
development of high antibody titers against peptide antigens
coupled to IRIVs [19,21]. There are already two well established
commercialized virosomal vaccines: the influenza vaccine Inflex-
alHV, and the hepatitis A vaccine EpaxalH. These vaccines induce
specific immunity without causing non-specific inflammatory
response and have therefore an excellent local tolerability in both
adults and children [22,23].
In a Phase 1a clinical trial virosomally formulated UK-39 and
AMA49-C1 was well-tolerated in malaria non-immune Cauca-
sian volunteers [24]. Both peptides elicited specific antibody
responses in all volunteers immunized through three injections.
Combined delivery of both peptides did not interfere with the
development of an antibody response to either of the antigens. In
a Phase 2a experimental sporozoite challenge trial in malaria
non-immune Caucasian volunteers, vaccine-related partial pro-
tection against sporozoite challenge was observed [25]. In the
same trial, vaccine-induced immune responses were boosted
under parasite challenge.
For this Phase 1b trial, UK-39 and AMA49-C1 were coupled to
the surface of lyophilizable IRIV formulations [26], rendering the
vaccine less sensitive to temperature changes and possible
instabilities of components which is particularly important for
vaccine application in sub-Saharan Africa [26]. The specific
objectives were to demonstrate safety, tolerability and immuno-
genicity in malaria semi-immune subjects.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study was conducted in compliance with ICH-GCP, the
Declaration of Helsinki, and local regulatory requirements. The
protocol and all related documents were approved by an
independent ethics committee in Switzerland (Ethikkommission
beider Basel, EKBB) as well as by the Institutional Review Board
of the Ifakara Health Institute and the Medical Research
Coordination Committee of the National Institute for Medical
Research in Tanzania through the Tanzanian Commission for
Science and Technology (COSTECH). The trial was registered at
www.ClinicalTrials.gov (NCT00513669).
Trial design
This was a prospective Phase 1b, single-center, randomized,
double-blind, controlled, age-deescalating study. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Protocol S1 and Checklist S1.
Participants
A total of 50 healthy subjects were enrolled; 10 adult male
volunteers 18–45 years of age and with a BMI of between 18 and
30, and 40 children of both sexes, 5–9 years of age with a mid-
upper arm circumference (MUAC) .12 cm. All subjects, or legal
representatives thereof, had given written informed consent.
Exclusion criteria were: use of any investigational drug or vaccine
within 30 days prior to study start or planned use during the study
period; chronic immunosuppressant therapy within 6 months prior
to study start; chronic medication; immunosuppressive or
immune-deficient condition including HIV infection; history of
allergic disease; acute disease at the time of enrolment (defined as
the presence of a moderate or severe illness with or without fever);
acute or chronic, clinically significant pulmonary, cardiovascular,
hepatic or renal functional abnormality; acute or chronic diabetes;
history of alcohol consumption and/or intravenous drug abuse.
Study setting
The study was performed at the Bagamoyo Research and
Training Unit of the Ifakara Health Institute (BRTU-IHI) from
January 2008 to March 2009. Subjects originated from the area
around Bagamoyo town, on the Tanzanian coast, 70 km north of
Dar-es-Salaam. Malaria transmission in this area is perennial and
almost entirely due to P. falciparum. Insecticide Treated Bednets
(ITN) are promoted through a national program. Artemether/
lumefantrine (CoartemH, Novartis, Switzerland) is currently the
first line treatment for P. falciparum malaria in Tanzania.
Intervention
The test vaccine PEV3B was composed of 50 mg AMA49-C1
(PEV301T) plus 10 mg UK-39 (PEV302T) peptides formulated in
virosomes in phosphate buffered solution pH 7.4 that was
subsequently lyophilized. PEV3B lyophilisate was supplied in
vials, and reconstituted with 0.6 mL water ,4 hours prior to
vaccination, of which 0.5 ml were injected. The comparator
InflexalHV is a commercially available virosomal influenza vaccine
(Crucell, Switzerland & The Netherlands). The trial vaccines and
comparator were administered i.m. in the left arm on day 0 and in
the right arm on day 90 (64 days). With respect to the first
vaccination, two adults were immunized before the remaining 8
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volunteers with a safety delay of 11 days (Figure 1). After an
additional safety observation period of 4 weeks, children were
immunized with a safety delay of 1 week between the first two
blocks. Subjects showing P. falciparum positive blood smears
without any clinical signs or symptoms were cleared from parasites
using artemether/lumefantrine prior to immunization. The
rationale for this pretreatment was to properly assess AEs following
immunization (AEFI) by excluding the potential confounding
effect of clinical malaria episodes often developing from asymp-
tomatic parasitaemia [27]. In case subjects presented with acute
disease (defined as the presence of a moderate or severe illness with
or without fever) or asymptomatic parasitaemia on the planned
date of second immunization, administration of the vaccine was
delayed upon resolution (end of AE or completion of artemether/
lumefantrine treatment).
Randomization and blinding
Randomization was computer-generated by an independent
statistician. The block of 10 adults (PEV3B n= 8, InflexalHV n=2)
was randomized separately. The 40 children were randomized in
blocks of 8 (PEV3B n= 6, InflexalHV n=2). A randomization
number (1 to 50) was assigned according to the sequence of
assignment of the subjects to the study and after inclusion/
exclusion criteria were confirmed by the investigator. Vaccines
were provided as kits labeled with the randomization number. The
trial vaccines and comparator were administered by an indepen-
dent pharmacist and/or nurse, with the investigators having no
access to the vaccination room. Syringes were covered using an
opaque foil in order to ensure blinding of the subjects.
Investigators and subjects remained blinded until the end of the
study and database lock.
Figure 1. Study flow chart.
doi:10.1371/journal.pone.0022273.g001
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Objectives
The primary objective was evaluation of safety and tolerability
of PEV3B in malaria semi-immune subjects. The secondary
objective was to measure the magnitude and duration of antibody
responses to the malaria specific antigens. Additional exploratory
objectives included measuring vaccine-induced cellular immune
responses (results to be presented elsewhere) and assessing
incidence of clinical episodes of malaria during the follow-up
period.
The sample size of this Phase 1b study was determined by the
requirement to demonstrate the safety and immunogenicity of the
virosome-formulated synthetic peptides. A sample size of 50
volunteers is considered appropriate to estimate incidence rate of
frequent AEs and assess immunogenicity with an acceptable
accuracy, still allowing for dropouts. Since the target population
for malaria vaccines are small children, the adult subgroup
included to assess vaccine safety in malaria exposed populations
was much smaller than the children group. The adult data are
presented for comparison with the children data, but it was not
intended to carry out detailed statistical analyses within the adult
subgroup. The rationale for an unbalanced allocation of study
vaccine and comparator within adult and children subgroups was
the main focus on safety and immunogenicity of the experimental
malaria vaccine and the established safety profile of the
comparator. To rule out that recorded anti-malaria antibody titer
increases are caused by cross-reactive immune responses to
influenza antigens, the small number of subjects immunized with
the comparator influenza vaccine was sufficient.
Outcomes
Safety. Occurrence of solicited local (pain, redness, swelling)
and solicited systemic (elevated temperature .37.5uC, headache,
fatigue, vertigo) adverse events (AEs) within 4 days after both
immunizations was assessed by the physician (see also Figure 1),
and general AEs were reported by the subjects throughout the
study until Day 365. Intensity of solicited local AEs was graded as
follows: pain: 0 = absent, 1 = painful on touch, 2 = painful on
movement, 3 = spontaneously painful; redness and swelling:
0 =,5 mm, 1= 5–20 mm, 2= 21–50 mm, 3=. mm. All other
AEs were graded and reported according to Common
Terminology Criteria for Adverse Events v3.0 (CTCAE).
Scheduled haematological and biochemical analyses were
performed at screening, baseline (day 0; day of 1st vaccination),
on days 7 (62), 90 (64; day of 2nd vaccination), and day 7 (62)
after 2nd vaccination.
Safety evaluation included the assessment of the incidence of
clinical malaria episodes. A blood sample was taken for
parasitological examination by microscopy from all subjects
presenting with a history of fever or raised temperature
(.37.5uC), irrespective of any other symptoms or sign.
Causality of AEs was categorized as related, probably related,
possibly related, unlikely related, and unrelated. All local solicited
AEs recorded within 4 days after each vaccination were considered
as related to the study vaccine.
Immunogenicity. Endpoint titers of anti-AMA49-C1 and
anti-UK-39 IgG were measured by ELISA at baseline and on days
30 (64), 90 (64; day of 2nd vaccination), 120 (64), 180 (67), and
day 365 (614). Procedures for analysis of antibody titers against
synthetic peptides using ELISA were described previously [24].
Endpoint titers were determined as last serum dilution where the
optical density (OD) of test sera was $26 OD of a negative
control serum pool of European donors. Swiss TPH and Pevion
Biotech AG performed two independent ELISA analyses.
Statistical methods
Safety. The safety analysis included all participants who
received at least one vaccination and for whom at least one set of
safety follow-up data was available. The proportions of subjects
experiencing a given category of AEs were compared using
Fisher’s exact test for differences between study vaccine and
comparator groups.
Immunogenicity. The per protocol (PP) population included
all participants, who received the two vaccinations in the allowed
intervals, attended all the scheduled blood sampling visits in the
allowed timeframe, and for whom no major protocol violation was
reported. The intention-to-treat (ITT) population included
subjects who received at least one vaccination, and for whom at
least one blood sample was taken.
Anti-AMA49-C1 and anti-UK-39 IgG endpoint titers were
measured by ELISA independently both at Swiss TPH and Pevion
Biotech AG. Endpoint titers obtained at Swiss TPH were, on
average, slightly higher compared to data from Pevion (p,0.05,
sign test, mean/median difference of log [endpoint titers] 0.8/0.7
for AMA49-C1 and 0.3/0 for UK-39), which is an expected
variation for repeated ELISA measurements. All statistical
analyses were run on the data from each lab separately, as well
as on the averaged data set (geometric mean). The identity of the
lab, as well as averaging the data, had no influence on the results of
the statistical analyses, and the results presented here are for the
averaged data set. The exact Wilcoxon test was used to test for
differences in endpoint titers between adults and children (at
baseline) and between treatment groups (separately for adults and
children for each sampling time point). Indices of antibody
responses were expressed as the ratio of endpoint titers after
immunization with reference to the baseline value (day 0).
Wilcoxon’s exact test was used to test for differences in indices
of antibody responses between treatment groups (separately for
adults and children for all time points post first vaccination).
In addition to the above analyses, which were specified in a
statistical analysis plan prior to final vaccine accountability and
unblinding, the following post-hoc exploratory analyses were
performed: 1) The area under the log (antibody titer)-curve above
the baseline antibody titer (DAUC) was calculated as an integrated
measure of antibody response for three intervals: days 0–30, 0–
120, and 0–365. DAUC values for anti-AMA49-C1 and anti-UK-
39 were compared between those subjects who were never tested
positive for P. falciparum during the respective interval and those
subjects who were tested positive at least once, and Wilcoxon’s
exact test was used to test for differences. 2) ELISA responders
were defined as subjects who seroconverted (from an endpoint titer
,50 to $50) or showed an at least 4-fold increase in endpoint titer
versus baseline. Fisher’s exact test was used to test for differences in
the proportions of responders between treatment groups (sepa-
rately for adults and children for all time points post first
vaccination). 3) Spearman’s rank correlations between anti-
AMA49-C1 and anti-UK-39 endpoint titers were computed for
each time point in each vaccine group.
Malaria morbidity. Time to first or only clinical malaria
episodes (confirmed parasitaemia plus clinical symptoms) in
children were compared using Kaplan-Meyer failure curves
from 30 days post first vaccination until the end of the study
(day 365). Difference between failure functions was assessed using
the log-rank test, and the hazard ratio was assessed using Cox
regression. This analysis had been specified in a statistical analysis
plan prior to unblinding. Following the new recommendation of
the WHO Malaria Vaccine Advisory Committee [28], we carried
out the same analysis separately for two sub-intervals: from day 30
after first vaccination until second vaccination (day 90), and from
Virosome Malaria Vaccine in Semi-Immune
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day 30 after second vaccination (day 120) until the end of the study
(day 365). In addition we assessed the treatment effect for multiple
episodes of clinical malaria post hoc, using Poisson regression,
including time at risk as an offset variable (differences were
evaluated using the log likelihood test). Children were not
considered susceptible for 28 days after the previous episode,
and not considered at risk for a period of 20 days after receiving
artemether/lumefantrine treatment and for a period of 7 days
after quinine alone [29].
Results
Participants
The participant flow is summarized in Figure 1. All 50 subjects
completed the study which lasted from 30 January 2008 (first
subject immunized) to 18 March 2009 (last subject completed the
study). Among adult volunteers (all male) mean age was 32 years in
the PEV3B group and 22 years in the InflexalHV group. In the
PEV3B children group 70% of the subjects were male, whereas
the gender ratio of the InflexalHV group was balanced (50%).
Mean age, weight, and MUAC were comparable between the
children groups (8 years, 19.8 kg, 166 mm for PEV3B, 8 years,
18.8 kg, 162 mm for InflexalHV). At screening hematology and
biochemistry results were generally comparable between the
vaccine groups (data not shown). 12 (40%) children in the PEV3B
group and 2 (20%) children in the InflexalHV group had positive
blood smears for P. falciparum parasites at screening (asymptom-
atic carriers). All were cleared from malaria with CoartemH
treatment before immunization.
Safety
All subjects were included in the safety analysis. Solicited (local
and general) and unsolicited (general) AEs occurring within 30
days after first and second vaccination are summarized in Table 1.
As there were only few AEs reported in adults and the statistical
power of test within adult groups was very low due to the small
number of subjects, we do not report any results of between-
treatment differences in proportion of adult subjects affected by
certain categories of AEs.
The only local solicited AEs (monitored from days 0–3 and 90–
93) were pain at the injection site, of which all were Grade 1,
required no action, and resolved without sequelae. With data
combined across both vaccinations the proportion of children
reporting pain at the injection site was lower for PEV3B compared
to InflexalHV (see data in Table 1, p = 0.014, Fisher’s exact test).
General solicited AEs (monitored from days 0–3 and 90–93)
reported in the study were elevated temperature (.37.5uC) and
headache; all of these occurred in children (Table 1). Elevated
temperature was reported in two (7%) PEV3B children and one
(10%) InflexalHV child after first vaccination, and in two (7%)
PEV3B children after second vaccination. Headache was reported
in two (7%) PEV3B children and one (10%) InflexalHV child after
second vaccination. Elevated temperature AEs were assessed as
‘‘related’’ (1 event in PEV3B group) or ‘‘probably related’’ (4
events) to the test vaccine, and all headache AEs as ‘‘possibly
related’’. Each of these events was Grade 1 or 2, required no
action or treatment with medication, and resolved without
sequelae.
All unsolicited AEs (monitored from days 0–365) in this study
were considered unrelated to the vaccine and resolved without
sequelae.
No statistically significant differences were observed between the
children vaccine groups for the proportions of subjects with any
AE within 30 days after vaccination, with any Grade 3 AE at any
time during the study, or with any related AE at any time during
the study (Table 1, p always .0.05, Fisher’s exact test).
Eight children (5 PEV3B and 3 InflexalHV) had serious AEs
(SAEs), which were primarily uncomplicated or complicated
malaria (definition of complicated malaria was parasitaemia
.5000/200 white blood cells). Each of the SAEs required
hospitalization and medication, all were considered unlikely
related or unrelated to study vaccine, and resolved without
sequelae.
No differences in hematology or biochemistry laboratory values
between the vaccine groups (adults and children) were observed
over the course of the study (data not shown).
Immunogenicity
The intention-to-treat population comprised 1 subject more
than the per protocol population (1 PEV3B child was excluded
due to a tetanus toxoid vaccine administered two weeks after
second vaccination). Since the exclusion of this subject had no
effect on the results of any statistical test, results presented in the
following sections are for the intention-to-treat analysis.
Table 1. Summary table of solicited (local and general) and
unsolicited (general) adverse events occurring within 30 days
after vaccination.
Adults Children
PEV3B InflexalHV PEV3B InflexalHV
N=8 N=2 N=30 N=10
After 1st vaccination (day 0–30)
Local solicited 1 13% - - 2 7% 1 10%
Pain 1 13% - - 2 7% 1 10%
General solicited - - - - 2 7% 1 10%
Elevated
temperature
- - - - 2 7% 1 10%
General,
unsolicited
7 63% 1 50% 30 67% 10 60%
After 2nd vaccination (day 90–120)
Local solicited - - - - 3 10% 5 50%
Pain - - - - 3 10% 5 50%
General solicited - - - - 4 13% 1 10%
Elevated
temperature
- - - - 2 7% - -
Headache - - - - 2 7% 1 10%
General,
unsolicited
2 25% - - 25 57% 11 70%
After 1st and 2nd vaccination (day 0–30 & day 90–120)
Any AE 10 88% 1 50% 66 77% 29 100%
Grade 3 AEs 0 0% 0 0% 4 13% 2 20%
Related AEs* 1 13% 0 0% 11 30% 8 70%
Notes: The term ‘‘related’’ refers to AEs judged to be at least possibly related to
the vaccine by the clinician. Local solicited AEs comprised pain, redness and
swelling, and were by default considered as related to the vaccine. General
solicited AEs comprised elevated temperature (.37.5uC), headache, fatigue and
vertigo, and all those reported in the table were considered related to the
vaccine. For solicited AEs detail on the different AEs are presented in non-bold
text.
*comprise all solicited and unsolicited AEs considered as related to the vaccine.
The data on AEs are shown as number of AEs and the proportion of subjects
affected.
doi:10.1371/journal.pone.0022273.t001
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Within the adult and children subgroups there were no a priori
differences in pre-vaccination anti-AMA49 and anti-UK-39 IgG
endpoint titers between the vaccine groups (Table 2, see also
Figure 2). The pre-inoculation anti-AMA49-C1 IgG endpoint
titers were higher in the adults (geometric mean 528; 95%-CI:
168–1657, n= 10) compared to the children (geometric mean 220;
95%-CI: 143–338, n= 40), but this difference was not significant
(p = 0.14, exact Wilcoxon test). For pre-vaccination anti-UK-39
IgG, the geometric mean of endpoint titers was significantly higher
in adults compared to children, 696 (95%-CI: 304–1594, n= 10)
and 54 (95%-CI: 39–73, n= 40), respectively (p,0.0001, exact
Wilcoxon test).
Table 2. Geometric means and corresponding 95% confidence intervals of anti-AMA-49-C1 and anti-UK-39 IgG ELISA endpoint
titres, and the rate of responders (in %) among subjects.
Adults Children
PEV3B InflexalHV p-value PEV3B InflexalHV p-value
N=8 N=2 N=30 N=10
AMA49-C1
Baseline 566 400 0.694 202 283 0.571
155–2067 - 127–323 88–910
Day 30 4935 119 0.036 2016 230 ,0.001
2669–9125 - 1234–3292 78–676
75% 0% 0.133 80% 0% ,0.001
Day 90 2577 100 0.035 857 207 0.005
1189–5584 - 521–1410 80–533
63% 0% 0.444 57% 10% 0.013
Day 120 8667 238 0.034 5572 200 ,0.001
3909–19218 - 3106–9994 72–558
75% 50% 1.000 87% 0% ,0.001
Day 180 4334 84 0.034 1695 180 ,0.001
2358–7964 - 967–2972 67–483
63% 0% 0.444 70% 10% 0.002
Day 365 3200 141 0.036 746 264 0.077
1280–8000 - 422–1320 96–725
75% 50% 1.000 50% 20% 0.145
UK-39
Baseline 835 336 0.426 49 68 0.353
298–2346 - 35–70 31–153
Day 30 7288 283 0.035 951 59 ,0.001
2843–18681 - 602–1502 26–136
63% 0% 0.444 93% 10% ,0.001
Day 90 5382 283 0.035 267 87 0.028
2072–13981 - 178–400 32–238
63% 0% 0.444 73% 10% 0.001
Day 120 6683 566 0.067 3275 81 ,0.001
2437–18330 - 1947–5507 31–212
63% 0% 0.444 97% 10% ,0.001
Day 180 4726 200 0.036 1213 64 ,0.001
1664–13424 - 736–1997 32–127
50% 0% 0.467 87% 10% ,0.001
Day 365 3342 141 0.036 356 54 ,0.001
1442–7743 - 229–554 23–123
50% 0% 0.467 83% 10% ,0.001
Notes: For InflexalHV adults no confidence interval for mean endpoint titers are shown because N= 2. ELISA responders were defined as subjects who seroconverted
(from an endpoint titer ,50 to $50) or showed an at least 4-fold increase in endpoint titer versus baseline. P-values are given for tests for differences between PEV3B
and InflexalHV within adult and children subgroups at the respective time point (exact Wilcoxon test for endpoint titers, Fisher’s exact test for the proportion of
responders).
doi:10.1371/journal.pone.0022273.t002
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The antibody endpoint titers for AMA49-C1 and UK-39 in the
PEV3B groups increased in response to the vaccinations as
measured 30 days after the first (day 30) and second (day 120)
immunization, whereas in the InflexalHV groups the endpoint
titers for both antigens remained at background levels (Figure 2).
However, on days 90 and 180 these titers had declined in the
PEV3B vaccinees (Figure 2). Endpoint titers were significantly
higher in the PEV3B vaccinees than in the InflexalHV control
group at all time points, except at day 120 for UK-39 in adults and
day 365 for AMA49-C1 in children (Table 2). In the PEV3B
group, endpoint titers were on average higher in adults than in
children, and this difference was significant at most sampling time
points (compare CIs in Table 2).
In PEV3B vaccinees, the average index of response for AMA49-
C1 (ratio of endpoint to baseline titers) ranged from 4.6 (day 90) to
15.3 (day 120) in adults and from 3.7 (day 365) to 27.5 (day 120) in
children. For UK-39, the index of response ranged from 4.0 (day
365) to 8.7 (day 30) among adults and from 5.4 (day 90) to 66.3
(day 120) among children (Figure 3). In both adults and children
PEV3B vaccinees, the average index of response was .1 for both
antigens at all sampling time points (Figure 3). The proportion of
responders to either antigen was significantly higher in PEV3B
than in InflexalHV children, except for AMA49-C1 at day 365
(Table 2).
Anti-AMA49-C1 and anti-UK-39 IgG endpoint titers were
significantly correlated with each other in PEV3B children at all
sampling points including baseline (Spearman’s rho r=0.50–0.61;
p always ,0.01). For the 8 PEV3B adults, the correlation was not
significant at any of the sampling points (r=20.51–0.56; p always
.0.15). In PEV3B vaccinated children, Spearman’s rho was
maximal at day 30 and day 120, indicating that the kinetics of
antibody responses to AMA49-C1 and UK-39 in response to
vaccination correlated with each other (data not shown).
Malaria morbidity
The proportion of children who experienced one or several
episode(s) of malaria from the first peak of endpoint titers (day 30)
until the end of the follow-up period (day 365) tended to be lower
in the PEV3B group than in the InflexalHV group (67% versus
80% respectively). However, the estimated failure functions were
not significantly different (incidence rate of first or only clinical
malaria episode per child-day IRfirst ep = 0.00514 for InflexalHV
and 0.00306 for PEV3B, p= 0.20; hazard ratio HRfirst ep and
95%-CI = 0.58 [0.24–1.36]) (Figure 4). For the period between 30
days after first vaccination until the second vaccination, the
proportion of children with at least one malaria episode was lower
in the PEV3B group than in the InflexalHV group (28% versus
73%). The difference in the corresponding failure functions was at
the threshold of statistical significance (IRfirst ep = 0.00676 for
InflexalHV and 0.00238 for PEV3B, p= 0.05; HRfirst ep = 0.31
[0.09–1.09]) (Figure 4). For the period from the highest measured
levels of antibody endpoint titers (30 days post second immuni-
zation, day 120) until the end of the study (day 365) the proportion
of children with at least one malaria episode was lower in the
PEV3B group than in the InflexalHV group (50% versus 80%).
The difference in the failure functions was marginally significant
(IRfirst ep = 0.00342 for InflexalHV and 0.00179 for PEV3B
respectively, p = 0.09; HRfirst ep = 0.48 [0.20–1.15]) (Figure 4).
The failure function for PEV3B children in the first panel of
Figure 4 shows a marked reduction of malaria events between
study days 150 and 220 which corresponds to the lower malaria
transmission in the dry period from mid-August to end of October.
The number of clinical malaria episodes per child subject from
day 30 after first vaccination until the end of the follow-up period
(day 365) was significantly lower in PEV3B vaccinees compared to
the control group (IR =0.0035 per day at risk for PEV3B and
0.0069 for InflexalHV, p=0.02). This corresponds to a reduction
of 50% (rate ratio RR =0.50, 95%-CI = 0.29–0.88).
For two adult subjects a clinical episode of malaria was reported
– both in the PEV3B group. Thus the proportion of adults affected
by malaria was lower than in children. This observation is in line
with the increased disease resistance of the adult population to
malaria, which therefore is not the target group for a malaria
vaccine.
Correlation between immunogenicity and malaria
morbidity
Among PEV3B children, those diagnosed with P. falciparum
parasitaemia (i.e. asymptomatic cases as well as clinical episodes)
during the study periods from day 0–30, day 0–120 and day 0–365
showed a lower integrated antibody response for UK-39 compared
to those who remained undiagnosed for P. falciparum parasitaemia
Figure 2. Development of anti-AMA49-C1 and anti-UK-39 IgG ELISA endpoint titres in adults and children immunized with PEV3B
or InflexalHV. Bars indicate 95% confidence intervals of the geometric mean (no bars are shown for adult InflexalHV, n = 2). Participants were
immunized on days 0 and 90 (see arrows).
doi:10.1371/journal.pone.0022273.g002
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(Figure 5). This difference between the two groups of children was
statistically significant for the periods day 0–30 and day 0–120
(Figure 5), indicating that UK-39-binding antibodies contribute to
prevention of malaria infection. During the study periods from day
0–120 and day 0–365, integrated antibody response for AMA49-C1
was also higher in children remaining undiagnosed for parasitae-
mia. However, for AMA49-C1 these differences were not
statistically significant.
Discussion
Phase 1a and 2a clinical trials conducted with virosomal
formulations of UK-39 and AMA49-C1 in malaria non-immune
Caucasian volunteers [24,25] have yielded encouraging results,
but did not address safety and immunogenicity of the vaccine
formulation in malaria semi-immune subjects.
The two commercialized virosome-based vaccines (EpaxalH and
InflexalHV) have already demonstrated the excellent safety profile
of the virosomal antigen delivery system. In the present trial, local
reactogenicity was minimal with only mild or moderate pain and
no grade 3 AE related to the vaccine reported. All SAEs were
considered unlikely or unrelated to the study vaccine and all
resolved without sequelae. This excellent reactogenicity profile
contrasts with results obtained with recombinant malaria proteins
formulated in ASO2A, ASO1E or Montanide ISA 720 & 51, or
DNA vaccines in viral vectors, which show much higher rates of
grade 2 and 3 AEs [30,31,32,33].
PEV3B elicited IgG responses to both target antigens in semi-
immune adults and children, with the highest titers generally
observed 30 days after the second immunization. 275 days after
the second immunization (day 365) endpoint titers against both
target antigens were still higher than baseline titers. In children,
the index of response to UK-39 tended to be stronger compared to
that to AMA49-C1, which was primarily due to the lower baseline
endpoint titers for UK-39. In adults, responses to both antigens
were comparable.
In this Phase 1b trial, malaria morbidity was not the primary
outcome, thus the design was not powered to assess efficacy.
However, the analysis of time to event for first or only episode of
clinical malaria in children suggests that the PEV3B had a
protective effect. There was no statistically significant difference in
incidence rate of first or only clinical malaria episode for the
period from 30 days after the first vaccination until the end of the
study on day 365. For two separate intervals, from day 30 after
first vaccination until second vaccination, and from day 30 after
second vaccination until the end of the study, however, the
reduction of incidence rate of first or only clinical malaria episode
by 70% and 50% respectively was approaching statistical
significance. These results, which look inconsistent at first glance,
are explained by the significantly higher rate of malaria episodes in
control subjects compared to PEV3B vaccinees. Multiple events in
the same subject are not captured in a conventional time-to-first-
event Kaplan-Meier graph. Data on the total number of episodes
are a better measure for the disease burden from a public health
perspective compared to first episode data [28]. In this study,
incidence rate of clinical malaria episodes in children vaccinated
with PEV3B was half the rate of the control group, and this
difference was statistically significant. A 50% efficacy to reduce
clinical malaria in children is equivalent to the protection
conferred by what is considered the most advanced malaria
vaccine to date, namely RTS,S, which indicates that the virosomal
platform with synthetic peptides represents a very promising
technology. For the analysis of data on multiple malaria episodes
we used the same methodology as Sacarlal et al. in their RTS,S
Figure 3. Box-plots of the logarithms of the index of response (ratios of anti-AMA49-C1 and anti-UK-39 IgG ELISA endpoint to
baseline titers) for samples taken at day 30, 90, 120, 180, and 365. AP: adults PEV3B, AI: adults InflexalHV, CP: children PEV3B, CI:
children InflexalHV. At all time points the logarithm of the index of response of AP and CP groups were significantly .0 (index of response .1,
p,0.05). This was never observed for the AI and CI groups. Symbols indicate the level of significance for differences in the index of response between
PEV3B and InflexalHV groups within adults and children subjects (exact Wilcoxon test, *: p,0.05, **: p,0.01, ***: p,0.001).
doi:10.1371/journal.pone.0022273.g003
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trial in Mozambican children [29]. However, multiple episodes in
the same subject are not independent from each other and the
analysis of such data requires more statistical research [28]. The
exploratory efficacy results from the present study are in line with
the measured antibody responses, and the indications for vaccine-
induced impact on asexual parasite blood stage multiplication in
the Phase 2a sporozoite challenge trial [25].
In the children PEV3B group, subjects with at least one episode
of P. falciparum parasitaemia in the study periods day 0–30 and
day 0–120 showed a significantly lower average response in
antibody titers against UK-39 for the corresponding period. For
anti-AMA49-C1 the differences in response of antibody titers
related to incidence of parasitaemia were not statistically
significant. This may indicate that the induced antibody response
to UK-39 is a key component of the possible protective effect of
PEV3B, and raises the question whether there is a link to the
pattern of differences in background antibody levels between the
Figure 4. Attack rates of first or only clinical malaria episodes
in vaccinated children. Kaplan-Meyer failure functions are shown for
the intervals from 30 days after first vaccination (day 30) until the end of
the study (day 365), from 30 days after first vaccination until second
vaccination (day 90), and from 30 days after second vaccination (day
120) until study end (day 365). P-values for differences in failure
functions between treatment groups are given (log-rank test). Note: the
failure function in the third panel is not identical with the
corresponding part of the failure function in the first panel, because
of the occurrence of multiple events in the same individual during the
course of the study.
doi:10.1371/journal.pone.0022273.g004
Figure 5. Comparison of the integrated antibody responses
against AMA49-C1 and UK-39 with the detection of malaria
parasitaemia in PEV3B children during time periods Day 0–30,
Day 0–120 and Day 0–365. DAUC was calculated as the area under
the log (antibody titer)-curve above the baseline antibody titer. DAUC
values were compared between those PEV3B children who did not have
positive smears for P. falciparum and those PEV3B children who were
tested positive for parasites using Wilcoxon’s test. The numbers (in
brackets) in the bars indicate the number of PEV3B in each of the
groups compared.
doi:10.1371/journal.pone.0022273.g005
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highly immune adult population and children. A close correlation
between anti-UK-39 IgG titers assessed in ELISA, immunofluo-
rescence and Western blotting analysis using sporozoites and
sporozoite lysates, respectively, has already been demonstrated
[10]. The anti-UK-39 antibody titers showed a close correlation to
in vitro inhibition of sporozoite migration and invasion of
hepatocytes [10].
The most advanced subunit malaria vaccine to date, RTS,S, is
currently tested in a phase III clinical trial (NCT00866619) and is
based on a fusion protein of part of the CSP of P. falciparum clone
3D7 (amino acids 207 – 395) with the hepatitis B surface antigen
[34].
Studies with RTS,S in an endemic area of Mozambique showed
that vaccination of children aged 1–4 years induced partial
protection against infection and clinical malaria including severe
disease [35]. RTS, S elicits strong humoral responses to the B cell
epitopes located in the central repeat region [34]. Evidence
accumulating over the years indicate strongly that high antibody
titres against the CSP correlate with protection [36]. These CSP-
specific antibodies may contribute to elimination of sporozoites
and infected hepatocytes by different mechanisms like neutraliza-
tion of sporozoites by inhibiting gliding motility and cell traversal,
Fc receptor-mediated engulfment of sporozoites, Fc-receptor
dependent lysis by NK and NKT cells or by activation of the
complement system after antibody binding.
Since IRIVs represent a modular antigen delivery system, they
are an ideal platform to evaluate individual antigens separately,
which can subsequently be combined with other components to a
multi-component subunit vaccine [24]. IRIV-based formulations
of additional malaria antigens have been optimized in pre-clinical
studies [21,37,38]. After individual clinical profiling they could be
added to the bivalent formulation tested in the present trial to form
a multivalent malaria vaccine. Our results indicate that by
conducting well-designed combined Phase 1b/2 trials in malaria
endemic regions, safety and immunogenicity can be assessed and
efficacy data can be obtained. These trials thus can represent an
important element in the rational design of an efficient malaria
multi-component vaccine, and could reduce time and cost of
development.
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